The High-Dose Aldesleukin “Select” Trial: A Trial to Prospectively Validate Predictive Models of Response Treatment in Patients with Metastatic Renal Cell Carcinoma

PURPOSE: High-dose aldesleukin (HD IL-2) received FDA approval for the treatment of mRCC in 1992, producing a 14% objective response rate (ORR) and durable remissions. Retrospective studies suggested that clinical and pathologic features could predict for benefit. The Cytokine Working Group conducte...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: McDermott, David F., Cheng, Su-Chun, Signoretti, Sabina, Margolin, Kim A., Clark, Joseph I., Sosman, Jeffrey A., Dutcher, Janice P., Logan, Theodore F., Curti, Brendan D., Ernstoff, Marc S., Appleman, Leonard, Wong, Michael K.K., Khushalani, Nikhil I., Oleksowicz, Leslie, Vaishampayan, Ulka N., Mier, James W., Panka, David J., Bhatt, Rupal S., Bailey, Alexandra S., Leibovich, Bradley C., Kwon, Eugene D., Kabbinavar, Fairooz F., Belldegrun, Arie S., Figlin, Robert A., Pantuck, Allan J., Regan, Meredith M., Atkins, Michael B.
Formato: Artigo
Idioma:Inglês
Publicado em: 2014
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4315731/
https://ncbi.nlm.nih.gov/pubmed/25424850
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-14-1520
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados